Sort   by:  
 Page size 
UnknownExploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
Not available
S-EPMC9870907 | biostudies-literature
UnknownEvaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
Not available
S-EPMC9400287 | biostudies-literature
UnknownDexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Not available
S-EPMC8488764 | biostudies-literature
UnknownPsychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study.
Not available
S-EPMC11332192 | biostudies-literature
UnknownTolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Not available
S-EPMC9615373 | biostudies-literature
UnknownValidation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
Not available
S-EPMC6868696 | biostudies-literature
UnknownSymptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Not available
S-EPMC7649863 | biostudies-literature
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Not available
S-EPMC7576974 | biostudies-literature
Sort   by:  
 Page size